After withdrawal, GSK’s Blenrep shows promise in phase 3 DREAMM-7 study

In November 2022, GSK began the process of withdrawing Blenrep’s U.S. marketing authorization after the phase 3 DREAMM-3 trial failed to show an overall survival benefit compared to standard therapy. But GSK has signaled its hope that the B-cell maturation antigen (BCMA) antibody-drug conjugate could have a new lease on life with new data from the phase 3 DREAMM-7 study.

Blenrep shows promise in DREAMM-7 study as combination therapy

The study revealed that combining Blenrep (belantamab mafodotin) with the proteasome inhibitor bortezomib and the steroid dexamethasone (BorDex) improved progression-free survival by 59% compared to a combination of Darzalex (daratumumab) and BorDex. Additionally, progression-free survival was extended to 36.6 months with Blenrep plus BorDex, versus only 13.4 months with the daratumumab regimen. Finally, the DREAMM-3 study found an early but strong and clinically meaningful trend toward improved overall survival favoring the Blenrep …

Read more
  • 0